1-20 of 30
François Ghiringhelli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT129: Immunity induction with atezolizumab, EIK1001, and radiotherapy in virus-associated tumors: Results of the AGADIR Trial

Free
Antoine Italiano, Carlos Gomez-Roca, François Ghiringhelli, Jean-Philippe Metges, Philippe Rochigneux, Aurelien Carnot, Florian Estrade, Marie-Paule Sablin, Pierre-Emmanuel Brachet, Nicolas Isambert, Jade Dupin, Sophie Cousin, Jean-Philippe Guegan, Alban Bessede, Marina Pulido, Paul Sargos
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT129.
https://doi.org/10.1158/1538-7445.AM2025-CT129
Published: 25 April 2025
View articletitled, Abstract CT129: Immunity induction with atezolizumab, EIK1001, and radiotherapy in virus-associated tumors: Results of the AGADIR Trial
Journal Articles

Abstract CT169: Phase Ib/II open-label, randomized study of atezolizumab + regorafenib + AB928 or atezolizumab + regorafenib vs regorafenib for patients with microsatellite-stable, refractory metastatic colorectal cancer in MORPHEUS-CRC

Free
James M. Cleary, Carlos Gomez-Roca, Francois Ghiringhelli, Joon Oh Park, Tae-You Kim, Brandon Beagle, Janelle Soong, Yibing Yan, Hans-Joachim Helms, Janet Lau, Edward Cha, Michel Ducreux
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT169.
https://doi.org/10.1158/1538-7445.AM2025-CT169
Published: 25 April 2025
View articletitled, Abstract CT169: Phase Ib/II open-label, randomized study of atezolizumab + regorafenib + AB928 or atezolizumab + regorafenib vs regorafenib for patients with microsatellite-stable, refractory metastatic colorectal cancer in MORPHEUS-CRC
Journal Articles

Abstract CT133: A phase 1b multicenter study of anti-TIM3 (S095018/Sym023) in combination with anti-PD1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer

Free
Francois Ghiringhelli, Richard Kim, Teresa Macarulla, Irene Moreno, Albiruni Razak, Jordi Rodon, Chih-Yi Liao, Thomas Marron, Judith Raimbourg, Helene Kaplon, Julia Geromini, Najah Harouki, Christelle Rodrigues, Pauline Darcel, Niels Jorgen Skartved, Rikke Hald, Daleen Lopez-Ravnborg, Peng He, Xenophon Ianopoulos, Vasileios Askoxylakis, Nehal J. Lakhani, Sarah Davis, Amit Mahipal
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT133.
https://doi.org/10.1158/1538-7445.AM2024-CT133
Published: 05 April 2024
View articletitled, Abstract CT133: A phase 1b multicenter study of anti-TIM3 (S095018/Sym023) in combination with anti-PD1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer
Journal Articles

Abstract CT054: Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study

Free
Byoung Chul Cho, Jonathan Goldman, Natasha Leighl, Filippo De Braud, Ki Hyeong Lee, François Ghiringhelli, Pilar Garrido, Julio Peguero, Benjamin Besse, Philippe Cassier, Nicolas Girard, Maria de Miguel, Rosa Alvarez, Alastair Greystroke, Yuichiro Ohe, Te-Chun Hsia, Joshua C. Curtin, Sanjib Chowdhury, Xuesong Lyu, Grace Gao, Siyang Qu, Patricia Lorenzini, Aastha Kapoor, Priya Kim, Mahadi Baig, Meena Thayu, Roland E. Knoblauch, Sandrine Hiret, Pascale Tomasini
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT054.
https://doi.org/10.1158/1538-7445.AM2024-CT054
Published: 05 April 2024
View articletitled, Abstract CT054: Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study
Journal Articles

Abstract CT217: First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b-2 trial

Free
Marion Thibaudin, Jean-David Fumet, Emeric Limagne, Léa Hampe, Susy Daumoine, Valentin Derangère, Caroline Laheurte, Olivier Adotevi, Caroline Truntzer, François Ghiringhelli
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT217.
https://doi.org/10.1158/1538-7445.AM2024-CT217
Published: 05 April 2024
View articletitled, Abstract CT217: First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b-2 trial
Journal Articles

Abstract 6408: Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) + best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2

Free
Sara Lonardi, Arvind Dasari, Rocio Garcia-Carbonero, Takayuki Yoshino, Pilar García-Alfonso, Judit Kocsis, Chiara Cremolini, François Ghiringhelli, Ardaman Shergill, Howard S Hochster, Michel Ducreux, Dirk Arnold, Varsha Sundaresan, Siddha Kasar, Adela Pina, Ziji Yu, William R Schelman, Lucy Chen, Josep Tabernero
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6408.
https://doi.org/10.1158/1538-7445.AM2024-6408
Published: 22 March 2024
View articletitled, Abstract 6408: Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) + best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2
Journal Articles

Abstract 7377: Deep learning uncovers morphological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients

Free
Benoit Schmauch, Vincent Cabeli, Omar Darwiche-Domingues, Jean-Eudes Le Douget, Alexandra Hardy, Reda Belbahri, Charles Maussion, Alberto Romagnoni, Markus Eckstein, Florian Fuchs, Aurélie Swalduz, Sylvie Lantuejoul, Hugo Crochet, François Ghiringhelli, Valentin Derangere, Caroline Truntzer, Harvey Pass, Andre Moreira, Luis Chiriboga, Yuanning Zheng, Michael Ozawa, Brooke Howitt, Olivier Gevaert, Nicolas Girard, Elton Rexhepaj, Iris Valtingojer, Laurent Debussche, Eric Durand, Marion Classe, Katharina Von Loga, Elodie Pronier, Matteo Cesaroni
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7377.
https://doi.org/10.1158/1538-7445.AM2024-7377
Published: 22 March 2024
View articletitled, Abstract 7377: Deep learning uncovers morphological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients
Journal Articles

Abstract 1188: Identification of CXCL10-inducing chemotherapy/targeted therapy combinations for PD-1 blockade sensitization in “cold” triple negative breast cancer

Free
Laura Kalfeist, Stacy Petit, Loick Galland, Cyriane Poirrier, Romain Aucagne, François Ghiringhelli, Sylvain Ladoire, Emeric Limagne
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1188.
https://doi.org/10.1158/1538-7445.AM2024-1188
Published: 22 March 2024
View articletitled, Abstract 1188: Identification of CXCL10-inducing chemotherapy/targeted therapy combinations for PD-1 blockade sensitization in “cold” triple negative breast cancer
Journal Articles

Abstract 1187: Sensitization to chemo-immunotherapy by targeting TGF-β in preclinical triple negative breast cancer models

Free
Laura Kalfeist, Fanny Ledys, Stacy Petit, Samia Kada-Mohammed, Mickael Rialland, François Ghiringhelli, Emeric Limagne, Sylvain Ladoire
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1187.
https://doi.org/10.1158/1538-7445.AM2024-1187
Published: 22 March 2024
View articletitled, Abstract 1187: Sensitization to chemo-immunotherapy by targeting TGF-β in preclinical triple negative breast cancer models
Journal Articles

Abstract 5003: Efficacy of the STC-1010 a new allogenic cancer vaccine in different colorectal cancer models

Free
George Alzeeb, Céline Gongora, Corentin Richard, Romain Boidot, Tanguy Fortin, Yan Wang, Alban Bessede, Benoit Pinteur, Lionel Chalus, Corinne Tortorelli, Paul Bravetti, François Ghiringhelli
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5003.
https://doi.org/10.1158/1538-7445.AM2024-5003
Published: 22 March 2024
View articletitled, Abstract 5003: Efficacy of the STC-1010 a new allogenic cancer vaccine in different colorectal cancer models
Journal Articles

Abstract 3864: Role of NK/TAM cross-talk on T-CD8+ recruitment and efficacy of chemoimmunotherapy and MEKi combination in "cold" tumors

Free
Lisa Nuttin, Charlène Latour, Solène Revy, Romain Aucagne, Guilhem Lalle, François Ghiringhelli, Emeric Limagne
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3864.
https://doi.org/10.1158/1538-7445.AM2024-3864
Published: 22 March 2024
View articletitled, Abstract 3864: Role of NK/TAM cross-talk on T-CD8+ recruitment and efficacy of chemoimmunotherapy and MEKi combination in "cold" tumors
Journal Articles

Abstract 6791: Inovative in vivo (in ovo) CAM model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on human colorectal adenocarcinoma

Free
Yan Wang, Arnaud Peyronnier, Benoit Pinteur, Lionel Chalus, Corinne Tortorelli, Paul Bravetti, Jean Viallet, François Ghiringhelli, Philippe Fornies
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6791.
https://doi.org/10.1158/1538-7445.AM2023-6791
Published: 04 April 2023
View articletitled, Abstract 6791: Inovative in vivo (in ovo) CAM model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on human colorectal adenocarcinoma
Journal Articles

Abstract 1296: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Free
Emeric Limagne, Lisa Nuttin, Marion Thibaudin, Elise Jacquin, Romain Aucagne, Marjorie Bon, Elise Ballot, Solène Revy, Robby Barnestein, Caroline Truntzer, Valentin Derangère, Jean-David Fumet, Rébé Cédric, Pierre-Simon Bellaye, Coureche-Guillaume Kaderbhai, Aodrenn Spill, Bertrand Collin, Mary Callanan, Aurélie Lagrange, Laure Favier, Bruno Coudert, Laurent Arnould, Sylvain Ladoire, Bertrand Routy, Philippe Joubert, François Ghiringhelli
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1296.
https://doi.org/10.1158/1538-7445.AM2022-1296
Published: 15 June 2022
View articletitled, Abstract 1296: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells
Journal Articles

Abstract 1284: The tumor scaffold protein SQSTM1 at the crossroads of DNA damage and immunotherapy responses in solid tumors

Free
Iris Grosjean, Grégoire D’Andréa, Nathalie Yazbeck, Amine Belaid, Barnabé Roméo, Marie Angela Domdom, Nicolas Guillot, Eric Gilson, Emmanuel Chamorey, Gérard Milano, Véronique Hofman, Marius Ilié, Isabelle Benard-Thiery, Simon Heeke, Patrick Brest, François Ghiringhelli, Paul Hofman, Baharia Mograbi
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1284.
https://doi.org/10.1158/1538-7445.AM2022-1284
Published: 15 June 2022
View articletitled, Abstract 1284: The tumor scaffold protein SQSTM1 at the crossroads of DNA damage and immunotherapy responses in solid tumors
Journal Articles

Abstract OT1-18-02: First-line chemo-immunotherapy with durvalumab, paclitaxel and carboplatin with or without anti-CD73 antibody oleclumab in advanced or metastatic triple-negative breast cancer: Preliminary results of the randomized phase II SYNERGY trial

Free
Veronique Debien, Christian Maurer, Philippe Aftimos, Florian Clatot, Delphine Loirat, Kevin Punie, François Ghiringhelli, Anhony Gonçalves, Donatienne Taylor, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, François Duhoux, Renaud Poncin, Fernando Bazan, Nicolas Isambert, Philippe Barthelemy, Mariana Brandão, Paulus Kristanto, Michail Ignatiadis, Martine Piccart, Laurence Buisseret
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT1-18-02.
https://doi.org/10.1158/1538-7445.SABCS21-OT1-18-02
Published: 15 February 2022
View articletitled, Abstract OT1-18-02: First-line chemo-immunotherapy with durvalumab, paclitaxel and carboplatin with or without anti-CD73 antibody oleclumab in advanced or metastatic triple-negative breast cancer: Preliminary results of the randomized phase II SYNERGY trial
Journal Articles

Abstract CT104: Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety results of the INTR@PID LUNG 024 study

Free
Christian Rolfo, Laurent Greillier, Remi Veillon, Firas Badin, Francois Ghiringhelli, Nicolas Isambert, Astrid Paulus, Marc Lambrechts, Italia Grenga, Xiaoli You, Andre Koenig, Sandrine Hiret
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT104.
https://doi.org/10.1158/1538-7445.AM2021-CT104
Published: 01 July 2021
View articletitled, Abstract CT104: Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety results of the INTR@PID LUNG 024 study
Journal Articles

Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance

Free
Antoine Bernard, Sandy Chevrier, Françoise Beltjens, Magalie Dosset, Etienne Viltard, Anaïs Lagrange, Valentin Derangère, Alexandra Oudot, François Ghiringhelli, Bertrand Collin, Lionel Apetoh, Olivier Feron, Suzie Chen, Laurent Arnould, Frédérique Végran, Romain Boidot
Journal: Cancer Research
Cancer Res (2019) 79 (23): 5958–5970.
https://doi.org/10.1158/0008-5472.CAN-19-0840
Published: 02 December 2019
View articletitled, Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance
Open the PDF for Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance in another window
Includes: Supplementary data
Journal Articles

Inactivation of Proprotein Convertases in T Cells Inhibits PD-1 Expression and Creates a Favorable Immune Microenvironment in Colorectal Cancer

Free
Mercedes Tomé, Angela Pappalardo, Fabienne Soulet, José Javier López, Jone Olaizola, Yannick Leger, Marielle Dubreuil, Amandine Mouchard, Delphine Fessart, Frédéric Delom, Vincent Pitard, Dominique Bechade, Mariane Fonck, Juan Antonio Rosado, François Ghiringhelli, Julie Déchanet-Merville, Isabelle Soubeyran, Geraldine Siegfried, Serge Evrard, Abdel-Majid Khatib
Journal: Cancer Research
Cancer Res (2019) 79 (19): 5008–5021.
https://doi.org/10.1158/0008-5472.CAN-19-0086
Published: 01 October 2019
View articletitled, Inactivation of Proprotein Convertases in T Cells Inhibits PD-1 Expression and Creates a Favorable Immune Microenvironment in Colorectal Cancer
Open the PDF for Inactivation of Proprotein Convertases in T Cells Inhibits PD-1 Expression and Creates a Favorable Immune Microenvironment in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract LB-190: Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas: a french sarcoma group study

Free
Maud Toulmonde, Nicolas Penel, Julien Adam, Christine Chevreau, Jean-Yves Blay, Axel Le Cesne, Emmanuelle Bompas, Sophie Piperno-neumann, Sophie Cousin, Thierry Ryckewaert, Alban Bessede, François Ghiringhelli, Marina Pulido, ANTOINE ITALIANO
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): LB-190.
https://doi.org/10.1158/1538-7445.AM2017-LB-190
Published: 01 July 2017
View articletitled, Abstract LB-190: Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas: a french sarcoma group study
Journal Articles

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Free
Emeric Limagne, Romain Euvrard, Marion Thibaudin, Cédric Rébé, Valentin Derangère, Angélique Chevriaux, Romain Boidot, Frédérique Végran, Nathalie Bonnefoy, Julie Vincent, Leila Bengrine-Lefevre, Sylvain Ladoire, Dominique Delmas, Lionel Apetoh, François Ghiringhelli
Journal: Cancer Research
Cancer Res (2016) 76 (18): 5241–5252.
https://doi.org/10.1158/0008-5472.CAN-15-3164
Published: 15 September 2016
View articletitled, Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Open the PDF for Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen in another window
Includes: Supplementary data